Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients Cheng-Long HanBao-Wen TianTao Li Review 22 February 2023 Pages: 1957 - 1969
Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer Aleksandra Semeniuk-WojtaśKarolina Poddębniak-StramaRafał Stec Review Open access 16 March 2023 Pages: 1971 - 1989
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients Berna C. ÖzdemirCristina Espinosa da SilvaSacha I. Rothschild Review Open access 05 April 2023 Pages: 1991 - 2001
Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients Berna C. ÖzdemirCristina Espinosa da SilvaSacha I. Rothschild Correction Open access 08 May 2023 Pages: 2003 - 2004
Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy Andrew C. JohnsMike YangCarolyn J. Presley Research 04 February 2023 Pages: 2005 - 2013
The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer Liying YangWei ZhangXiaorong Sun Research 04 February 2023 Pages: 2015 - 2027
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody Noriyuki NishiwakiKazuhiro NomaToshiyoshi Fujiwara Research Open access 10 February 2023 Pages: 2029 - 2044
Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer Yao-Jun YuNa ShanZhen-Zhai Cai Research Open access 16 February 2023 Pages: 2045 - 2056
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma Shuhei YamadaHaruka MiyataToshihiko Torigoe Research 16 February 2023 Pages: 2057 - 2065
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy Mingjia LiSongzhu ZhaoDwight H. Owen Research 16 February 2023 Pages: 2067 - 2074
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort Tyler J. NielsenMatthew G. VargaKimberly McGregor Research Open access 19 February 2023 Pages: 2075 - 2086
Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy Toshihiro NagatoHiroki KomatsudaHiroya Kobayashi Research 22 February 2023 Pages: 2087 - 2098
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial A. S. FeilsA. K. ErbeP. M. Sondel Research Open access 23 February 2023 Pages: 2099 - 2111
Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines Carmen Aguilar-GurrieriAna BarajasJorge Carrillo Research Open access 23 February 2023 Pages: 2113 - 2125
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors Fabiana PerroneElda FavariSebastiano Buti Research 24 February 2023 Pages: 2127 - 2135
Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC Ting LiJiang GuoFanpu Ji Research Open access 25 February 2023 Pages: 2137 - 2149
Mitochondrial C1QBP is essential for T cell antitumor function by maintaining mitochondrial plasticity and metabolic fitness Hui TianDafei ChaiJunnian Zheng Research 25 February 2023 Pages: 2151 - 2168
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study Airi FujimotoYoshimichi KoutakeYosei Kawamata Research 27 February 2023 Pages: 2169 - 2178
LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells Peitao WuYuhang GuoZhiyuan Qian Research Open access 28 February 2023 Pages: 2179 - 2193
Correction to: LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells Peitao WuYuhang GuoZhiyuan Qian Correction Open access 17 April 2023 Pages: 2195 - 2196
Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study Yunchao WangXiaobo YangHaitao Zhao Research 01 March 2023 Pages: 2197 - 2204
Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma Yu TanakaTokiko NakaiGenichiro Ishii Research 02 March 2023 Pages: 2205 - 2215
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach Andrea BotticelliAlessio CirilloPaolo Marchetti Research Open access 03 March 2023 Pages: 2217 - 2231
M2 tumor-associated macrophages resist to oxidative stress through heme oxygenase-1 in the colorectal cancer tumor microenvironment Misato ItoKosaku MimuraKoji Kono Research 04 March 2023 Pages: 2233 - 2244
MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy Jin JinTianjiao LiuJianfeng Zhou Research Open access 04 March 2023 Pages: 2245 - 2256
Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004) Si-Yang LiuQixun ChenYi-Long Wu Research 05 March 2023 Pages: 2257 - 2265
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma Nathaniel DasyamKatrina J. SharplesIan F. Hermans Research Open access 07 March 2023 Pages: 2267 - 2282
Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation Yun-Shan LinShu-Fen ChiangKevin Chih-Yang Huang Research 07 March 2023 Pages: 2283 - 2297
Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study Lushan XiaoYanxia LiaoLi Liu Research 08 March 2023 Pages: 2299 - 2308
HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study Meiting ChenKai YaoXin An Research Open access 10 March 2023 Pages: 2309 - 2318
CiTSA: a comprehensive platform provides experimentally supported signatures of cancer immunotherapy and analysis tools based on bulk and scRNA-seq data Feng LiKejing DongXia Li Research 13 March 2023 Pages: 2319 - 2330
Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia Jiali ChengTong GeLiang Huang Research Open access 17 March 2023 Pages: 2331 - 2346
Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs Fumihiro FujikiSoyoko MorimotoHaruo Sugiyama Research Open access 20 March 2023 Pages: 2347 - 2356
A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer Liv Cecilie Vestrheim ThomsenAlfred HonoréChristian Beisland Research Open access 20 March 2023 Pages: 2357 - 2373
Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire Douglas G. MillarS. Y. Cindy YangPamela S. Ohashi Research Open access 21 March 2023 Pages: 2375 - 2392
IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy Aiqin GuYue BaiXiaosong Zhong Research 29 March 2023 Pages: 2393 - 2403
Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors Ruben V. Huis in ‘t VeldSen MaMartine J. Jager Research Open access 30 March 2023 Pages: 2405 - 2422
Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC Shasha WangGuangyu FanXiaohong Han Research 03 April 2023 Pages: 2423 - 2442
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors Johanna BendellPatricia LoRussoSandip Pravin Patel Research Open access 05 April 2023 Pages: 2443 - 2458
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist Alexander A. PieperDan V. SpiegelmanPaul M. Sondel Research Open access 05 April 2023 Pages: 2459 - 2471
Combined therapeutic effect of YHO-1701 with PD-1 blockade is dependent on natural killer cell activity in syngeneic mouse models Hiroyuki TakahashiNao MiyoshiAkira Asai Research 05 April 2023 Pages: 2473 - 2482
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating Yize MaoHui XieWei Wang Research 06 April 2023 Pages: 2483 - 2498
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells Anetta MarcinekBettina BrauchleMarion Subklewe Research Open access 11 April 2023 Pages: 2499 - 2512
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells Anetta MarcinekBettina BrauchleMarion Subklewe Correction Open access 08 May 2023 Pages: 2513 - 2514
Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden Michael H. StorandtNguyen TranAminah Jatoi Brief Report 06 March 2023 Pages: 2515 - 2520
Anti-PD-1 therapy in advanced sarcomas: is cutaneous primary site a stronger predictor of response than histologic subtype? Ruoyu MiaoJennifer SwankAndrew S. Brohl Brief Report Open access 13 March 2023 Pages: 2521 - 2527
BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia Christian Sordo-BahamondeSeila Lorenzo-HerreroSegundo Gonzalez Brief Report Open access 11 April 2023 Pages: 2529 - 2539
Cancer immunity and immunotherapy beyond COVID-19 Matteo BelloneArianna BreviMario Paolo Colombo Meeting Report 30 March 2023 Pages: 2541 - 2548